KCNQ1 and gastric cancer: For example, a retrospective study identified KCNQ1 rs163182 as an independent predictor of treatment response in gastric cancer patients who received first-line EOF chemotherapy (epirubicin, oxaliplatin, and 5-fluorouracil), but it failed to find significant associations of rs163182 variants with OS or progression-free survival of patients with gastric cancer[30].